Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Chao Jiang , Zhao Zixu Added: 5 days ago
AHA Scientific Sessions 2025 – Dr Chao Jiang and Dr Zhao Zixu (Beijing Anzhen Hospital, CN) discuss the findings from the DARE-AF (NCT06433479) randomized clinical trial, investigating whether dapagliflozin reduces atrial fibrillation burden following catheter ablation in patients without diabetes or heart failure.This single-center, open-label trial enrolled 200 patients with persistent atrial… View more
Added: 3 months ago Source:  Radcliffe Cardiology
The decision to switch frail, elderly patients with atrial fibrillation (AF) from a stable vitamin K antagonist (VKA) regimen to a direct-acting oral anticoagulant (DOAC) remains a subject of clinical debate. A new substudy from the COMBINE-AF dataset provides clarity, suggesting that while the switch reduces severe outcomes like stroke and death, it does not lower the risk of major bleeding and… View more
Author(s): Renato D Lopes Added: 1 year ago
ESC Congress 24 — AF screening with a wearable ECG device increases diagnosis by over 50% but did not significantly reduce hospitalisation rates for stroke.We are joined onsite at ESC Congress 2024 by Dr Renato Lopes (Duke University Medical Center, NC) to discuss the findings from the GUARD-AF Trial (NCT04126486, Bristol-Myers Squibb), which was designed to determine if screening for undiagnosed… View more
Author(s): Mads Brix Kronborg Added: 2 years ago
ESC 2023 — Dr Mads Brix Kronborg (Aarhus University Hospital, DE) joins us to discuss the findings from the DANPACE II Trial (NCT00236158). DANPACE II (The DANPACE Investigator Group) trial aimed to compare patients who were randomised in a 1:1 ratio to either a base rate of 60 beats per minute and rate-adaptive DDD (DDDR-60 Group) or a base rate of 40bpm and non-rate adaptive DDD (DDD-40… View more
Added: 3 months ago Source:  Radcliffe Cardiology
Vasovagal syncope (VVS) is a common and challenging condition with limited effective treatments, affecting a significant portion of the general population during their lifetime.² While elastic compression stockings (ECS) have been proposed as a non-pharmacological therapy to prevent recurrence, their real-world effectiveness has remained uncertain. A new multicentre, randomised, sham-controlled… View more
Added: 2 months ago Source:  Arrhythmia Academy
A strategy of actively increasing plasma potassium to high-normal levels significantly lowered the risk of arrhythmia events in high-risk patients with an implantable cardioverter–defibrillator (ICD), according to results from the POTCAST trial.¹˒² The findings were presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously published in the New England Journal of… View more
Added: 3 months ago Source:  Radcliffe Cardiology
A large-scale, nationwide study from South Korea suggests that vaccination with the live zoster vaccine is associated with a significantly lower risk of various cardiovascular (CV) events in adults aged 50 and older. The findings indicate a protective association that persists for up to 8 years post-vaccination.¹This population-based cohort study analysed data from over 2.2 million individuals… View more
Author(s): Joost Daemen , Nicolas M Van Mieghem Added: 3 months ago
Dive into our coverage of ESC Congress 2025 for groundbreaking trial results and discussions with expert faculty.Watch ourView From the Thoraxcenterseries for practice-focused reviews of the most anticipated trials from interventional experts,Prof Nicolas Van MieghemandDr Joost Daemen. Watch our Wrap-Upseries led byDr Mirvat Alasnag summarising the key take-aways from each day of the congress.For… View more
Research Area(s) / Expertise: Job title: Associate Professor and Senior Consultant
Dr Lund's expertise is in HF big data and registry-based comparative outcomes studies and pragmatic trials. He is active in programs to improve utilisation of existing evidence-based interventions in heart failure with reduced ejection fraction, as well as in novel interventions. Dr Lars Lund is an Editorial Board member ofCardiac Failure Review. View more